Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.73 |
| ▸ | ALDH3A1 | P30838 | 8/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | CA12 | O43570 | 2/20 | 0.65 |
| ▸ | CA1 | P00915 | 2/20 | 0.65 |
| ▸ | CA2 | P00918 | 2/20 | 0.65 |
| ▸ | CA9 | Q16790 | 2/20 | 0.65 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.65 |
| ▸ | CES2 | O00748 | 1/20 | 0.64 |
| ▸ | BCHE | P06276 | 1/20 | 0.64 |
| ▸ | CES1 | P23141 | 1/20 | 0.64 |
| ▸ | PARK7 | Q99497 | 3/20 | 0.61 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | CASP7 | P55210 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29870136 | 0.91 | ALDH3A1 (0.74) | CHRM5ALDH3A1ALDH1A1CA12CA1 | |
| SCHEMBL11186018 | 0.88 | ALDH3A1 (0.82) | CHRM5ALDH3A1ALDH1A1CA12CA1 | |
| SCHEMBL29869527 | 0.88 | ALDH3A1 (0.82) | CHRM5ALDH3A1ALDH1A1CA12CA1 | |
| SCHEMBL10979016 | 0.87 | ALDH1A1 (0.69) | CHRM5ALDH3A1ALDH1A1CA12CA1 | |
| SCHEMBL578265 | 0.87 | PARK7 (0.74) | CHRM5ALDH3A1ALDH1A1CA12CA1 | |
| SCHEMBL30937981 | 0.85 | CHRM5 (1.00) | CHRM5ALDH3A1ALDH1A1CA12CA1 | |
| SCHEMBL3021031 | 0.83 | CHRM5 (0.72) | CHRM5ALDH3A1ALDH1A1CA12CA1 | |
| SCHEMBL4597228 | 0.82 | ACHE (0.77) | ALDH3A1ALDH1A1CA12CA1CA2 | |
| SCHEMBL4597560 | 0.82 | ACHE (0.86) | CHRM5ALDH3A1ALDH1A1CA12CA1 | |
| SCHEMBL22410741 | 0.81 | ACHE (0.75) | CHRM5ALDH3A1ALDH1A1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008046083-A2 | USE OF OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
| EP-1877378-A2 | OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-01-16 | — | — | EP | disclosed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | disclosed |
| WO-2006113864-A2 | OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | OPRL1, OPRK1, TRPV1 | CHRM5 355/4885ALDH3A1 1159/4885ALDH1A1 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.